10 SEP 2026 · KEYNOTE
From in vivo CAR-T to AI-native PCV: Byterna presents programmable immunity at BIOHK 2026
At BIOHK 2026 in Hong Kong, co-founder and CEO Andy Xian Zeng, Ph.D., presented Byterna’s integrated strategy spanning transient, non-integrating in vivo CAR-T and AI-guided personalized neoantigen cancer vaccines.
The presentation connected circular mRNA engineering, cell-selective delivery and integrated manufacturing for in vivo CAR-T with Neodiscovery.ai-supported, patient-specific neoantigen combination design for personalized cancer vaccines.
The two therapeutic directions share an integrated development system while retaining distinct product designs, evidence requirements and development plans.